Earnings ·
Co-Diagnostics reported second quarter 2026 financial results with revenue of $0.17 million and a net loss of $6.3…
CODXCo-Diagnostics, Inc.
Co-Diagnostics reported second quarter 2026 financial results with revenue of $0.17 million and a net loss of $6.3 million, or $1.46 per share, compared to a net loss of $7.7 million in the prior year period. The company completed a $3.0 million private placement priced at-the-market under Nasdaq rules to strengthen its balance sheet, which held $3.6 million in cash as of June 30, 2026. Operational milestones included submitting an FDA 510(k) application for the Co-Dx PCR Flu A/B & RSV test and appointing Wes Lindsey as Chief Scientific Officer. The company also expanded commercial outreach through a European trade mission and initiated clinical studies in India for its tuberculosis diagnostic platform. Co-Diagnostics operates in the molecular diagnostics industry, developing and manufacturing integrated testing platforms and assays.